Commentary: Treatment of Femoropopliteal In-Stent Restenosis for Patients With Diabetes: Do We Have an Answer to the DEBATE?

Newer generation nitinol stents have im-proved outcomes following treatment of moderate length superficial femoral and pop-liteal artery lesions, but restenosis still occurs in up to 40 % of cases.1–3 In real-world practice, stenting is commonly performed for femoropopliteal lesions exceeding 150 mm in length, in which the likelihood of restenosis is even higher.4–6 Femoropopliteal in-stent re-stenosis (FP-ISR) therefore remains an impor-tant and frequent clinical problem.7 A number of technologies have been studied for the treatment of FP-ISR, including laser atherec-tomy, excisional atherectomy, cutting balloon angioplasty, and repeat stenting with covered